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ABSTRACT
Objectives: This post hoc analysis of TIOtropium Safety
and Performance In Respimat (TIOSPIR) evaluated safety
and exacerbation efficacy in patients with stable
(≥2 months) use of tiotropium HandiHaler 18 µg (HH18)
prior to study entry, to evaluate whether there was a
difference in risk for patients who switched from HH18 to
tiotropium Respimat 2.5 µg (R2.5) or 5 µg (R5).
Setting: TIOSPIR (n=17 135) was an international,
Phase IIIb/IV, randomised, double-blind, parallel-group,
event-driven trial.
Participants: Patients from TIOSPIR with chronic
obstructive pulmonary disease (COPD) and
postbronchodilator ratio of forced expiratory volume in
1 s to forced vital capacity ≤0.70, receiving HH18 before
study entry, were analysed (n=2784).
Interventions: Patients were randomised to once-daily
tiotropium R2.5 (n=914), R5 (n=918) or HH18 (n=952)
for 2–3 years.
Primary and secondary outcome measures:
Primary outcomes: time to death (safety) and time to first
COPD exacerbation (efficacy). Secondary outcomes:
number of exacerbations and time to first major adverse
cardiovascular event (MACE).
Results: Baseline characteristics were similar in all
groups. Respimat had a similar mortality risk versus
HH18 (vital status follow-up, HR; 95% CI R2.5: 0.87;
0.64 to 1.17; R5: 0.79; 0.58 to 1.07) with no significant
differences in the risk and rates of exacerbations and
severe exacerbations across treatment groups. Risk of
MACE and fatal MACE was similar for Respimat versus
HH18 (HR; 95% CI MACE R2.5: 0.73; 0.47 to 1.15; R5:
0.69; 0.44 to 1.08; fatal MACE R2.5: 0.57; 0.27 to 1.19;
R5: 0.67; 0.33 to 1.34). Overall risk of a fatal event (on
treatment) was lower for R5 versus HH18 (HR; 95% CI
R2.5: 0.78; 0.55 to 1.09; R5: 0.62; 0.43 to 0.89).
Conclusions: This analysis indicates that it is safe to
switch patients from tiotropium HandiHaler to tiotropium
Respimat, and that the efficacy is maintained over the
switch.
Trial registration number: NCT01126437; Post-
results.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is a major cause of death and
disability worldwide.1 Tiotropium bromide is
a once-daily, long-acting anticholinergic
(long-acting muscarinic antagonist (LAMA))
and an established treatment option for
COPD (SPIRIVA, Boehringer Ingelheim,
Ingelheim, Germany). It is available in two
formulations: a dry powder delivered via the
HandiHaler device (18 µg once daily) and
Strengths and limitations of this study
▪ This post hoc analysis examined whether there
was a difference in mortality or efficacy between
those patients who were previously stable users
(≥2 months) of tiotropium HandiHaler and con-
tinued with this delivery system during TIOSPIR
and those who were subsequently randomised to
tiotropium Respimat. This study will therefore be
informative for physicians who are contemplating
switching their patients from one inhaler to
another.
▪ Being one of the largest, long-term, random-
ised trials of a broad range of patients with
chronic obstructive pulmonary disease (COPD)
conducted to date, TIOSPIR lends itself to
statistically powerful subgroup analyses. The
inclusion of a wide range of spirometrically
defined disease severities and the liberal inclu-
sion criteria permitted a patient population that
was highly representative of a typical COPD
population (including patients with cardiac
disorders).
▪ The results of this study are more robust than
findings from meta-analyses or database studies,
which typically evaluate less frequent outcomes
or rare events that may not be as rigorously col-
lected as primary or secondary events, and in
which confounding factors (such as disease
severity) may not be fully adjusted for. A key
limitation of the study is that it was a post hoc
rather than predefined subgroup analysis. In
addition, the design of the analysis does not
allow for an evaluation of treatment initiation
with the two inhalers in anticholinergic-naïve
patients (results for this patient group are the
subject of a separate analysis).
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an aqueous solution delivered via the Respimat Soft Mist
Inhaler (5 µg once daily).2 3 Tiotropium HandiHaler
and Respimat have demonstrated similar improvements
in lung function, symptoms and quality of life; they have
similar pharmacokinetic proﬁles in patients with
COPD.4–8
There is a large body of evidence supporting the clin-
ical efﬁcacy and safety of tiotropium administered via
HandiHaler in patients with COPD.6 Safety concerns,
however, were prompted after results of a post hoc
pooled analysis of several trials (and subsequent
meta-analyses) indicated a signal of increased risk of
mortality with tiotropium Respimat, notably in patients
with a history of cardiac arrhythmias.9–14 A pooled ana-
lysis of tiotropium HandiHaler studies, as well as the
4-year Understanding Potential Long-term Impacts on
Function with Tiotropium (UPLIFT) (NCT00144339)
study,8 15 16 did not indicate such a risk, with rate ratios
favouring tiotropium HandiHaler versus placebo.
Nevertheless, a possible interpretation of data from add-
itional studies14 17 could have suggested a speciﬁc risk
associated with tiotropium Respimat.
The TIOtropium Safety and Performance In Respimat
(TIOSPIR) (NCT01126437) trial18 19 was conducted to
provide a prospective evaluation of the safety and exacer-
bation efﬁcacy of tiotropium Respimat versus tiotropium
HandiHaler. TIOSPIR is the largest long-term, random-
ised, double-blind study in patients with COPD per-
formed to date. It demonstrated that the risk of death
was similar for tiotropium Respimat, at a dose of 2.5 or
5 µg, to that of HandiHaler 18 µg, with a HR of 0.96 for
tiotropium Respimat 5 µg versus HandiHaler 18 µg. The
risk of exacerbation and major adverse cardiovascular
(CV) events (MACEs) did not differ signiﬁcantly among
the three groups.19
Despite providing reassurance on the safety of
Respimat versus HandiHaler, the results from TIOSPIR
have continued to raise some important questions
regarding the two formulations. In particular, a popula-
tion cohort study of patients aged ≥45 years receiving
tiotropium identiﬁed several factors that inﬂuenced the
likelihood of switching from HandiHaler to Respimat.20
These included COPD severity and comorbidities
(notably neurological conditions).20 The authors of the
study concluded that tiotropium users in clinical practice
typically have more severe disease than patients included
in randomised clinical trials and, therefore, called for
further studies comparing the safety proﬁle of the two
tiotropium formulations.20
This post hoc analysis of TIOSPIR was conducted to
address these concerns and to assess whether there was
a difference in safety or efﬁcacy between patients who
had already received stable treatment with tiotropium
HandiHaler and continued with this delivery system, and
those who were subsequently randomised to tiotropium
Respimat.
METHODS
Study design
TIOSPIR was a long-term (2–3 years), international, mul-
ticentre, Phase IIIb, randomised, double-blind, double-
dummy, parallel-group, actively controlled, event-driven
trial in a large population (n=17 135) of patients with
COPD. The study design has been described
previously.18
Patients were randomised to one of three treatments:
once daily tiotropium Respimat 2.5 μg (two puffs of
1.25 µg) or 5 µg (two puffs of 2.5 µg) or once daily
tiotropium HandiHaler 18 μg. The study did not include
a washout period from COPD treatments prior to ran-
domisation. Patients attended clinic visits every 12 weeks,
with a ﬁnal visit 30 days after the end of treatment; all
were followed up for vital status until the end of the
study, even if their treatment was discontinued.
The trial was performed in accordance with the
Declaration of Helsinki, and the study protocol and pro-
cedures were approved by the relevant institutional
review boards and ethics committees. All patients pro-
vided written informed consent.
Study population
Tiotropium HandiHaler 18 μg was the only LAMA mar-
keted (tiotropium Respimat was not available) at the
time of study enrolment (May 2010–April 2011) in the
following countries: Australia, Canada, China, Georgia,
Guatemala, India, Israel, New Zealand, Switzerland,
Thailand, Tunisia and the USA. This subgroup analysis
included patients with stable LAMA use prior to study
enrolment (in the previous 2 months prior to visit 1)
who were recruited from 339 centres across these coun-
tries, resulting in a population restricted to patients
using tiotropium HandiHaler 18 μg.
Patients were aged ≥40 years with a clinical diagnosis
of COPD, postbronchodilator ratio of forced expiratory
volume in 1 s (FEV1) to forced vital capacity ≤0.70,
FEV1≤70% predicted, and had ≥10 pack-years of
smoking history.
Exclusion criteria were chosen to select a typical
COPD population. Patients with concomitant cardiac
Strengths and limitations of this study
▪ A further limitation of the study is that information on duration
of treatment with tiotropium HandiHaler prior to randomisation
and switch to Respimat was not collected. These data would
provide additional valuable information on the characteristics
of the patients enrolled in the study (eg, the proportion of
patients who may have been considered more ‘stable’ on treat-
ment with tiotropium due to a longer duration of therapy than
other patients).
▪ The current analysis also excluded patients with
moderate-to-severe renal impairment; however, placebo-
controlled studies of patients with moderate renal impairment
do not indicate an increased risk in these patients with the use
of tiotropium Respimat.
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disease were permitted to participate in the study, unless
they had experienced a myocardial infarction (MI)
within the previous 6 months, were hospitalised for
New York Heart Association class III or IV heart failure,
or had a history of unstable or life-threatening arrhyth-
mia requiring new treatment within the previous
12 months. In addition, patients with unstable COPD
(exacerbation within 4 weeks), moderate or severe renal
impairment as judged by the investigator, or other sig-
niﬁcant lung diseases, were excluded.
Patients were permitted to use their usual background
treatment for COPD, except for other inhaled
anticholinergics.
Assessments
The primary safety outcome was time to death from any
cause (non-inferiority for Respimat 2.5 and 5 µg vs
HandiHaler 18 μg) and the primary efﬁcacy outcome
was time to ﬁrst COPD exacerbation (superiority for
Respimat 5 µg vs HandiHaler 18 μg). COPD exacerba-
tions were deﬁned as the worsening of two or more
major respiratory symptoms (dyspnoea, cough, sputum,
chest tightness or wheezing) with a duration of at least
3 days and requiring speciﬁed treatment changes. Mild
exacerbations required a newly prescribed maintenance
bronchodilator; moderate exacerbations required a pre-
scription for antibiotics, systemic corticosteroids or both;
and severe exacerbation required hospitalisation.
Secondary outcomes included the number of COPD
exacerbations, time to ﬁrst moderate or severe exacerba-
tion, time to ﬁrst severe (hospitalised) exacerbation and
time to non-fatal and fatal MACE (MACE included
stroke, transient ischaemic attack, MI, sudden death,
cardiac death, sudden cardiac death or fatal event in the
system organ classes (SOCs) for cardiac and vascular dis-
orders). SOCs were deﬁned according to the Medical
Dictionary for Regulatory Activities.
Adverse event (AE) collection included all serious
AEs, related AEs and AEs leading to discontinuation.
All AEs and deaths were reviewed by an independent
data and safety monitoring committee. In addition, all
deaths were reviewed by an independent mortality adju-
dication committee (blinded to study-group assign-
ments). For the non-fatal MACEs (stroke and MI)
reported by site investigators, the accuracy of diagnosis/
classiﬁcation was veriﬁed by central reviewers, who were
blinded to the study-group assignments.
Statistical analysis
HRs and 95% CIs for time-to-event end points were cal-
culated using a Cox-proportional hazards regression
model (with no covariate adjustment). Negative bino-
mial regression models were used to compare annual
exacerbation rates. Non-inferiority testing for the risk of
death was performed using HandiHaler 18 μg as the ref-
erence treatment. Rate ratios and 95% CI were used to
compare incidence rates.
For analysis of death (including fatal MACE), events
occurring during treatment and vital status follow-up
(follow-up for deaths even if the patient discontinued
early) were considered (vital status analysis), while for all
other analyses (including MACE and COPD exacerba-
tions), only events with onset in the on treatment period
were noted.
For the two primary outcomes, analyses on predeﬁned
subgroups speciﬁed by demographic variables, comorbid
conditions, disease severity and concomitant medica-
tions, were performed.
RESULTS
Study population
A total of 2784 patients from TIOSPIR who received
stable tiotropium HandiHaler 18 µg prior to study entry
were randomised and treated with blinded medication,
and included in the analyses of mortality (tiotropium
Respimat 2.5 µg: n=914; 5 µg: n=918; HandiHaler 18 µg:
n=952). A total of 2782 patients were analysed for all
other end points (two patients were excluded because
they were from centres with data irregularities); baseline
characteristics for this population are shown in table 1.
Mean observation time (including vital status follow-up)
was 858 days. In total, 679 patients (tiotropium Respimat
2.5 µg: n=229; 5 µg: n=211; HandiHaler 18 µg: n=239)
prematurely discontinued from trial medication, includ-
ing because of deaths.
Patient demographics and baseline characteristics
were similar in the three tiotropium groups (table 1).
The mean age of patients was 67.2 years, the majority
(61.3%) were male, 29.8% were current smokers and
mean postbronchodilator FEV1 was 46.2% of pre-
dicted. The majority of patients were Global Initiative
for Chronic Obstructive Lung Disease Stages II
(40.8%) and III (45.0%). Overall, 68.7% of patients
were taking a long-acting β2-agonist at baseline and a
similar proportion of patients (66.5%) were taking
inhaled corticosteroids. The majority (60.1%) of
patients were also receiving CV medications at base-
line and 16.2% of patients had a history of cardiac
arrhythmia (the most common type being atrial ﬁbril-
lation or ﬂutter; table 1).
Mortality end points
Both Respimat doses were non-inferior to HandiHaler
with respect to the primary end point of time to death
(vital status analysis)—Respimat 2.5 µg: HR 0.87; 95%
CI 0.64 to 1.17; 5 µg: HR 0.79; 95% CI 0.58 to 1.07
(ﬁgure 1). In a sensitivity analysis, the risk of a fatal AE
was lower in the Respimat 5 µg versus the HandiHaler
group (HR 0.62; 95% CI 0.43 to 0.89; Respimat 2.5 µg:
HR 0.78; 95% CI 0.55 to 1.09) (see E-ﬁgure 1). Causes
of death were similar across the treatment groups,
including death from cardiac disorders and MACE.
Although the incidence of cardiac disorders was higher
in the HandiHaler group (n=5 vs 2), the very small
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Table 1 Patient baseline characteristics
Characteristic
Tiotropium
Respimat
2.5 μg
(n=914)
Tiotropium
Respimat
5 μg
(n=917)
Tiotropium
HandiHaler
18 μg
(n=951)
Gender, n (%)
Male 551 (60.3) 568 (61.9) 585 (61.5)
Female 363 (39.7) 349 (38.1) 366 (38.5)
Age, mean years (SD) 67.3 (8.6) 67.4 (8.8) 66.9 (8.9)
BMI, mean kg/m2 (SD) 27.2 (6.3) 26.9 (6.2) 26.8 (6.2)
Current smoker, n (%) 262 (28.7) 278 (30.3) 290 (30.5)
Smoking history, mean pack-years (SD) 51.9 (28.6) 51.4 (29.0) 52.7 (28.7)
Postbronchodilator spirometry, mean (SD)
FEV1, L 1.21 (0.46) 1.25 (0.47) 1.24 (0.46)
FEV1, % predicted 45.8 (14.2) 46.7 (13.9) 46.1 (13.7)
FVC, L 2.62 (0.86) 2.65 (0.87) 2.64 (0.89)
Ratio of FEV1 to FVC 0.47 (0.12) 0.48 (0.11) 0.48 (0.11)
GOLD stage, n (%)
I+II 367 (40.2) 398 (43.4) 375 (39.4)
III 411 (45.0) 398 (43.4) 443 (46.6)
IV 128 (14.0) 117 (12.8) 124 (13.0)
Previous cardiac arrhythmia, n (%) 154 (16.8) 138 (15.1) 158 (16.6)
Atrial fibrillation or flutter 56 (6.1) 50 (5.5) 57 (6.0)
Bundle branch block 51 (5.6) 39 (4.3) 35 (3.7)
Ventricular fibrillation 3 (0.3) 3 (0.3) 4 (0.4)
Supraventricular tachycardia 7 (0.8) 7 (0.8) 16 (1.7)
Ventricular tachycardia 6 (0.7) 5 (0.5) 10 (1.1)
Bradycardia 14 (1.5) 18 (2.0) 25 (2.6)
Atrioventricular block 12 (1.3) 10 (1.1) 16 (1.7)
Other conduction disorders 25 (2.7) 27 (2.9) 28 (2.9)
Previous MI, n (%) 79 (8.6) 91 (9.9) 99 (10.4)
Previous stroke, n (%) 21 (2.3) 24 (2.6) 27 (2.8)
Previous IHD or CAD, n (%) 154 (16.8) 149 (16.3) 184 (19.3)
Taking CV medication, n (%) 554 (60.6) 551 (60.1) 568 (59.7)
β-blockers 169 (18.5) 178 (19.4) 190 (20.0)
Calcium channel blockers 164 (17.9) 175 (19.1) 174 (18.3)
Cardiac glycosides 22 (2.4) 19 (2.1) 28 (2.9)
ACE inhibitors 221 (24.2) 210 (22.9) 209 (22.0)
Angiotensin receptor blockers 111 (12.1) 128 (14.0) 127 (13.4)
Nitrates 40 (4.4) 46 (5.0) 49 (5.2)
Antiarrhythmics class I or III
(sodium or potassium channel blockers)
6 (0.7) 8 (0.9) 15 (1.6)
Acetylsalicylic acid 276 (30.2) 300 (32.7) 281 (29.5)
Anticoagulants* 52 (5.7) 45 (4.9) 41 (4.3)
Antiplatelets 55 (6.0) 55 (6.0) 63 (6.6)
Use of respiratory medication
LAMA 914 (100.0) 917 (100.0) 951 (100.0)
LABA 637 (69.7) 631 (68.8) 644 (67.7)
SABA 615 (67.3) 601 (65.5) 628 (66.0)
ICS 613 (67.1) 612 (66.7) 626 (65.8)
β-adrenergics 615 (67.3) 601 (65.5) 628 (66.0)
LRTA 50 (5.5) 49 (5.3) 56 (5.9)
Mucolytics 35 (3.8) 39 (4.3) 44 (4.6)
Supplemental oxygen 123 (13.5) 120 (13.1) 122 (12.8)
Xanthines 92 (10.1) 73 (8.0) 88 (9.3)
Two patients from centres with data irregularities were excluded.
*Includes vitamin K antagonists, direct thrombin inhibitors, factor Xa inhibitors.
ACE, angiotensin converting enzyme; BMI, body mass index; CAD, coronary artery disease; CV, cardiovascular; FEV1, forced expiratory
volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; IHD,
ischaemic heart disease; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LRTA, leucotriene receptor antagonist; MI,
myocardial infarction; SABA, short-acting β2-agonist.
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number of cardiac deaths, the small absolute risk differ-
ence and the wide CIs around the HRs, do not indicate
any signiﬁcant difference (table 2).
No signiﬁcant treatment interactions were observed
for either Respimat dose compared with HandiHaler in
the subgroups of patients with baseline cardiac
Figure 1 Kaplan–Meier plot of
time to death by treatment
(vital status analysis).
Table 2 Adjudicated primary causes of death (vital status analysis)
Variable
Tiotropium
Respimat
2.5 μg
(n=914)
Tiotropium
Respimat
5 μg
(n=918)
Tiotropium
HandiHaler
18 μg
(n=952)
Rate ratio (95% CI)
Tiotropium
Respimat
2.5 μg vs
HandiHaler 18 μg
Tiotropium
Respimat
5 μg vs
HandiHaler 18 μg
Adjudicated causes of death,
n (rate/100 patient-years)
77 (3.6) 71 (3.3) 92 (4.1) 0.87 (0.64 to 1.17) 0.79 (0.58 to 1.07)
Cardiac disorders 2 (0.1) 2 (0.1) 5 (0.2) 0.41 (0.08 to 2.14) 0.41 (0.08 to 2.10)
General disorders 12 (0.6) 14 (0.6) 18 (0.8) 0.69 (0.33 to 1.43) 0.79 (0.39 to 1.59)
Neoplasms benign, malignant
and unspecified
25 (1.2) 16 (0.7) 18 (0.8) 1.44 (0.79 to 2.64) 0.91 (0.46 to 1.78)
Respiratory, thoracic and
mediastinal disorders
29 (1.4) 26 (1.2) 33 (1.5) 0.91 (0.55 to 1.50) 0.80 (0.48 to 1.34)
COPD 28 (1.3) 25 (1.1) 28 (1.3) 1.04 (0.61 to 1.75) 0.91 (0.53 to 1.56)
Infections and infestations 6 (0.3) 6 (0.3) 4 (0.2) 1.55 (0.44 to 5.51) 1.53 (0.43 to 5.42)
Nervous system disorders 2 (0.1) 1 (0.0) 4 (0.2) 0.52 (0.09 to 2.83) 0.25 (0.03 to 2.28)
Patients with fatal MACE,
n (rate/100 patient-years)
11 (0.5) 13 (0.6) 20 (0.9) 0.57 (0.27 to 1.19) 0.66 (0.33 to 1.33)
Sudden death 5 (0.2) 8 (0.4) 5 (0.2) 1.04 (0.30 to 3.58) 1.63 (0.53 to 4.98)
Sudden cardiac death 2 (0.1) 0 (0.0) 5 (0.2) 0.41 (0.08 to 2.14) –
Cerebrovascular accident 1 (0.0) 1 (0.0) 4 (0.2) 0.26 (0.03 to 2.32) 0.25 (0.03 to 2.28)
Cardiac failure congestion 1 (0.0) 1 (0.0) 1 (0.0) 1.04 (0.06 to 16.56) 1.02 (0.06 to 16.29)
Acute myocardial infarction 1 (0.0) 0 (0.0) 0 (0.0) – –
Aortic dissection 0 (0.0) 0 (0.0) 1 (0.0) – –
Aortic valve stenosis 0 (0.0) 0 (0.0) 1 (0.0) – –
Arteriosclerosis 0 (0.0) 1 (0.0) 0 (0.0) – –
Cardiac failure chronic 0 (0.0) 0 (0.0) 1 (0.0) – –
Cardiac valve disease 0 (0.0) 1 (0.0) 0 (0.0) – –
Cor pulmonale 0 (0.0) 0 (0.0) 1 (0.0) – –
Myocardial infarction 0 (0.0) 0 (0.0) 1 (0.0) – –
Peripheral vascular disorder 0 (0.0) 1 (0.0) 0 (0.0) – –
Subarachnoid haemorrhage 1 (0.0) 0 (0.0) 0 (0.0) – –
Time at risk adjusted rate ratios of adjudicated causes of death by treatment, MedDRA (V.16.0) system organ class and preferred term.
COPD, chronic obstructive pulmonary disease; MACE, major adverse cardiovascular event (stroke, transient ischaemic attack, myocardial
infarction, sudden death, cardiac death, sudden cardiac death or fatal event in the system organ classes for cardiac and vascular disorders);
MedDRA, Medical Dictionary for Regulatory Activities.
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Table 3 Risk and rate of exacerbations (on treatment analysis*)
Variable
Tiotropium
Respimat
2.5 μg
(n=914)
Tiotropium
Respimat
5 μg
(n=917)
Tiotropium
HandiHaler
18 μg
(n=951)
HR (95% CI); p value
Tiotropium Respimat
2.5 μg vs HandiHaler
18 μg
Tiotropium Respimat
5 μg vs HandiHaler
18 μg
Any exacerbation
Patients with event, n (%) 573 (62.7) 560 (61.1) 578 (60.8) 1.03 (0.92 to 1.16);
p=0.614
0.96 (0.86 to 1.08);
p=0.517
Number of events 1484 1508 1548
Adjusted rate of events/patient-year (95% CI) 0.83 (0.77 to 0.91) 0.83 (0.76 to 0.90) 0.81 (0.74 to 0.87)
Moderate-to-severe exacerbation
Patients with event, n (%) 561 (61.4) 550 (60.0) 571 (60.0) 1.01 (0.90 to 1.14);
p=0.817
0.96 (0.85 to 1.07);
p=0.441
Number of events 1462 1474 1525
Adjusted rate of events/patient-year (95% CI) 0.82 (0.75 to 0.89) 0.81 (0.74 to 0.88) 0.79 (0.73 to 0.86)
Severe (hospitalised) exacerbation
Patients with event, n (%) 172 (18.8) 173 (18.9) 172 (18.1) 1.04 (0.85 to 1.29);
p=0.690
1.03 (0.84 to 1.28);
p=0.760
Number of events 264 283 267
Adjusted rate of events/patient-year (95% CI) 0.15 (0.13 to 0.18) 0.16 (0.13 to 0.19) 0.14 (0.12 to 0.17)
Two patients from centres with data irregularities were excluded.
*Includes first day after treatment stop.
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arrhythmia (Respimat 2.5 µg: HR 1.03; 95% CI 0.58 to
1.84; 5 µg: HR 0.83; 95% CI 0.44 to 1.56) or cardiac
history deﬁned as history of MI, ischaemic heart disease/
coronary artery disease, cardiac arrhythmia or heart
failure (Respimat 2.5 µg: HR 1.01; 95% CI 0.65 to 1.57;
5 µg: HR 0.93; 95% CI 0.59 to 1.46) (see E-ﬁgure 2a, b).
Exacerbation efficacy
There was no difference in the primary end point of
time to ﬁrst COPD exacerbation (on treatment) in
either of the Respimat groups versus HandiHaler (HR
1.03; 95% CI 0.92 to 1.16; and HR 0.96; 95% CI 0.86
to 1.08 for Respimat 2.5 and 5 µg vs HandiHaler,
respectively) (table 3 and E-ﬁgure 3a). The median
time to ﬁrst exacerbation was 390 and 466 days in the
Respimat 2.5 and 5 µg groups, respectively, and
418 days in the HandiHaler group. The number of
exacerbations was similar between the treatment groups
(adjusted rate/patient-year: 0.83, 0.83 and 0.81 in the
Respimat 2.5 or 5 µg and HandiHaler groups,
respectively).
No difference was observed between the
Respimat-treated population and HandiHaler groups
with respect to the secondary end points of time to ﬁrst
moderate-to-severe exacerbation and time to ﬁrst severe
(hospitalised) exacerbation (table 3; E-ﬁgure 3b, c). The
frequency of moderate-to-severe and hospitalised exacer-
bations was low and similar between treatment groups
(table 3). No signiﬁcant treatment interactions were
observed for either of the Respimat doses versus
HandiHaler for the predeﬁned subgroups with respect
to exacerbation risk.
Other safety end points
Serious AEs were reported in 42.5% of patients, with
similar frequencies between each treatment group
(table 4).
For the secondary safety end points of time to ﬁrst
MACE, there was no signiﬁcant difference between the
Respimat and HandiHaler groups (table 4 and E-ﬁgure
4a, b). The incidence of ﬁrst MACE was 3.5% in the
Respimat 2.5 µg group, 3.4% in the 5 µg group and
4.8% in the HandiHaler group (on treatment analysis,
based on adjudicated causes of death) (table 4) (HR
0.73; 95% CI 0.47 to 1.15, p=0.179; and HR 0.69; 95%
CI 0.44 to 1.08, p=0.107 for Respimat 2.5 and 5 µg vs
HandiHaler, respectively).
Table 4 Summary of AEs and MACE by treatment (on treatment analysis*)
Variable
Tiotropium
Respimat
2.5 μg
(n=914)
Tiotropium
Respimat
5 μg
(n=917)
Tiotropium
HandiHaler
18 μg
(n=951)
Any AE, n (%) 711 (77.8) 721 (78.6) 737 (77.5)
Drug-related AEs, n (%) 73 (8.0) 66 (7.2) 75 (7.9)
Respiratory, thoracic and mediastinal disorders 42 (4.6) 37 (4.0) 31 (3.3)
Gastrointestinal disorders 16 (1.8) 15 (1.6) 18 (1.9)
Nervous system disorders 11 (1.2) 3 (0.3) 6 (0.6)
Cardiac disorders 2 (0.2) 1 (0.1) 8 (0.8)
Serious AEs, n (%)† 373 (40.8) 399 (43.5) 409 (43.0)
Respiratory, thoracic and mediastinal disorders 198 (21.7) 203 (22.1) 212 (22.3)
Infections and infestations 118 (12.9) 115 (12.5) 110 (11.6)
Neoplasms—benign, malignant and unspecified
(including cysts and polyps)
71 (7.8) 73 (8.0) 65 (6.8)
Cardiac disorders 50 (5.5) 56 (6.1) 71 (7.5)
Nervous system disorders 26 (2.8) 31 (3.4) 34 (3.6)
General disorders and administration-site conditions 18 (2.0) 24 (2.6) 30 (3.2)
Renal and urinary disorders 11 (1.2) 12 (1.3) 15 (1.6)
Patients with MACE, n (%)‡ 34 (3.7) 31 (3.4) 57 (6.0)
Myocardial infarction 8 (0.9) 6 (0.7) 11 (1.2)
Cerebrovascular accident 6 (0.7) 6 (0.7) 10 (1.1)
Transient ischaemic attack 4 (0.4) 11 (1.2) 6 (0.6)
Patients with MACE, n (%)§ 32 (3.5) 31 (3.4) 46 (4.8)
Two patients from centres with data irregularities were excluded.
*Includes thirty days after treatment stop.
†Frequency of patients with serious AEs, as determined by the investigator, occurring in 15 or more patients at the MedDRA (V.16.0)
preferred term level by treatment and primary system organ class.
‡Frequency of patients with AEs classified as MACE, as determined by the investigator, occurring in 10 or more patients at the preferred term
level by treatment and primary system organ class.
§Frequency of patients with AEs classified as MACE based on adjudicated causes of death.
AE, adverse event; MACE, major adverse cardiovascular event (stroke, transient ischaemic attack, myocardial infarction, sudden death,
cardiac death, sudden cardiac death or fatal event in the system organ classes for cardiac and vascular disorders); MedDRA, Medical
Dictionary for Regulatory Activities.
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DISCUSSION
This post hoc analysis of TIOSPIR demonstrated that
patients receiving stable (≥2 months) treatment with
tiotropium HandiHaler 18 µg at baseline who changed
to treatment with tiotropium Respimat 2.5 or 5 µg were
at a similar (though numerically lower) risk of death
and MACE as patients who continued to receive
HandiHaler 18 µg. It also found that recipients of tiotro-
pium Respimat had a similar risk of exacerbation as
those receiving tiotropium HandiHaler. These ﬁndings
are consistent with the TIOSPIR study results.
Evidence from previous studies, primarily retrospect-
ive analyses, has raised concerns that tiotropium deliv-
ered by Respimat may be associated with adverse CV
effects in patients with CV comorbidities.9–14 17
Approximately 16% of patients in this post hoc analysis
had a history of cardiac arrhythmias. The subgroup ana-
lyses in patients with a history of cardiac arrhythmia and
those with cardiac history, predeﬁned in the main study,
demonstrated no signiﬁcant difference between
Respimat and HandiHaler recipients with respect to
mortality and exacerbation risk; in line with the main
study, no increased risk could be identiﬁed, even in the
subgroup of patients who changed from HandiHaler to
Respimat.
There was a 38% reduced risk of fatal AEs in the
Respimat 5 µg group versus the HandiHaler group.
Together with a numerical (though not statistically sig-
niﬁcant) imbalance in favour of both Respimat doses
with respect to incidence of ﬁrst MACE, this argues
against any deleterious effect of tiotropium when given
using Respimat. Importantly, previous studies of long-
term treatment of patients with COPD with tiotropium
Handihaler in the 4-year UPLIFT study did not indicate
any adverse effect on MACE or fatal MACE versus
placebo.8
Other recent studies have provided additional support
for the safety of Respimat in patients with COPD.
A pharmacokinetic study4 showed that, although
the overall proﬁle was similar, systemic exposure to
tiotropium following the use of tiotropium Respimat was
slightly lower compared with tiotropium HandiHaler.
A post hoc analysis of mortality and exacerbation
data from six clinical trials of tiotropium Respimat and
tiotropium HandiHaler (including UPLIFT and
TIOSPIR) showed similar effects on both, mortality and
exacerbations, between Respimat 5 µg and HandiHaler
18 µg.21 In addition, risk of exacerbation was lower for
both tiotropium formulations versus placebo, with
numerically higher efﬁcacy for Respimat 5 μg.21 In
another study, combined analysis of all trials from the
tiotropium clinical trial database involving Holter-ECG
monitoring in patients with COPD did not demonstrate
any clinically relevant differences between Respimat and
HandiHaler with respect to changes in heart rate or in
the proportion of patients experiencing supraventricular
or ventricular premature beats while on tiotropium.22
Finally, a pooled analysis of AE data from 28 randomised
trials of HandiHaler and seven Respimat studies did not
indicate a signiﬁcantly increased risk of fatal AEs or
fatal/non-fatal MACE with either inhaler versus
placebo.23
A recent drug utilisation study investigated the
inﬂuence of factors on the probability of receiving
tiotropium HandiHaler or Respimat and determined
the existence of a channelling effect both in incident
users and in patients switching from the HandiHaler to
the Respimat formulation.20 It found that comorbidities
and disease severity inﬂuence the likelihood of switching
from HandiHaler to Respimat, and called for further
studies comparing the safety proﬁle of the two formula-
tions.20 The present study addresses any safety and
efﬁcacy concerns regarding the switch between
formulations.
TIOSPIR is the largest COPD study conducted to date,
comprising over 34 000 patient-years of exposure to
tiotropium.19 Clinical trials are often criticised for not
recruiting patients typical of the population treated in
routine clinical practice. The liberal inclusion criteria of
the TIOSPIR study permitted a large number of patients
to be included, with a wide range of disease severities
and history of cardiac disorders; it was thus representa-
tive of a typical COPD population (although it excluded
patients with severe, unstable CV disease or
moderate-to-severe renal impairment). In addition, the
large size of the population allowed for statistically
powerful subgroup analyses.
The results of TIOSPIR can be regarded as more robust
than ﬁndings from meta-analyses or database studies,
which typically evaluate less frequent outcomes from clin-
ical studies that may not have been collected as rigorously
as primary or secondary outcome measures.24 Database
studies evaluating rare events may not fully adjust con-
founding by severity; for example, it is difﬁcult to interpret
the independent effect of tiotropium Respimat without a
detailed assessment of underlying COPD and CV risk.24
Furthermore, differences often exist in the populations
studied, doses of treatment and length of follow-up.
A limitation of the study is the post hoc design involv-
ing a subgroup of patients with a lower number of
patients than in the main study. The design of this post
hoc analysis does not allow for an evaluation of treat-
ment initiation with the two inhalers in anticholinergic-
naïve patients; results for these patients will be reported
elsewhere.
This post hoc analysis was restricted to patients who
were receiving tiotropium HandiHaler 18 µg treatment
for at least 2 months prior to randomisation. It is unfor-
tunate that data on the duration of treatment outside of
the 2-month cut-off period were not collected, as this
would facilitate better characterisation of the patients
who were included in the study. For example, patients
who had been treated with tiotropium HandiHaler for
longer than 2 months could be considered more ‘stable’
on this treatment than patients who were recently
initiated on tiotropium.
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While the current analysis excluded patients with
moderate-to-severe renal impairment, placebo-controlled
studies of patients with moderate renal impairment do
not indicate an increased risk in these patients with the
use of tiotropium Respimat.25 26 A pooled safety analysis
of 22 Phase III and IV clinical trials of tiotropium
HandiHaler and Respimat (N=10 805 patients) demon-
strated no trend for increased incidence rate ratios of
AEs with worsening renal function for either formula-
tion.25 26 In this current post hoc analysis, the group of
patients with severe renal impairment was too small to
be analysed.
CONCLUSION
This post hoc analysis of the pivotal TIOSPIR trial pro-
vides additional evidence for the safety of tiotropium
delivered by Respimat, which demonstrated a similar
safety proﬁle to tiotropium HandiHaler in patients with
COPD, including those with a history of cardiac disor-
ders. Based on this analysis, it can be concluded that it
is safe to switch patients from tiotropium HandiHaler to
tiotropium Respimat, and that the efﬁcacy is maintained
over the switch.
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